{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:34:22Z","timestamp":1792683262957,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Denosumab is authorized to treat several diseases, including cancer and bone disorders. Nevertheless, its use in clinical practice has been affected by safety concerns. The work retrospectively investigated adverse events (AEs) of denosumab to better understand toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The FAERS data base data from Q1 of 2010 to Q3 of 2023 was chosen. The definition of Medical Dictionary for Regulatory Activities (MedDRA) was dependent on preferred terms (PTs) and system organ class (SOCs). Following the removal of duplicate reports, a disproportionality analysis was conducted to identify safety signals through the calculation of reporting odds ratios (ROR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the reporting period, 130611 denosumab-related cases were identified; 670\u00a0<jats:italic>p<\/jats:italic>Ts with a substantial disproportionality were retained. The connective and musculoskeletal tissue disorders, poisoning, injury, and procedural complications, as well as medical and surgical procedures, were among the important SOCs that satisfied the criteria. Reports at PT levels including off-label use, death, osteonecrosis of the jaw, arthralgia, and pain in extremities were determined. Severe consequences in terms of life-threatening injuries and death accounted for 841 and 19704 cases, respectively of the reported cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings underscore the critical importance of pharmacovigilance and are consistent with established clinical observations. Notably, osteonecrosis of the jaw, arthralgia, pain in extremities, back pain, myalgia, and bone pain were identified as the most prevalent risk signals associated with denosumab.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1339721","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T05:08:15Z","timestamp":1724994495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab"],"prefix":"10.3389","volume":"15","author":[{"given":"Yue","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Arug administration adverse event reporting system (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"Cd012432","DOI":"10.1002\/14651858.CD012432.pub2","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"7","author":"Beth-Tasdogan","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin. Oral Implants Res."},{"key":"B5","first-page":"596","article-title":"A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives","volume":"22","author":"Chatziravdeli","year":"2022","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"B6","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J. Clin. Densitom."},{"key":"B9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul","year":"2021","journal-title":"Arch. Osteoporos."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1007\/s12325-020-01395-x","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, randomized controlled phase 3 study-asian subgroup analysis","volume":"37","author":"Huang","year":"2020","journal-title":"Adv. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 Years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00198-023-06838-z","article-title":"Neuropsychiatric adverse reactions in patients treated with denosumab: two case reports and a review of data from the FDA Adverse Event Reporting System (FAERS)","volume":"34","author":"Oteo-\u00c1lvaro","year":"2023","journal-title":"Osteoporos. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0269216316639793","article-title":"Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project","volume":"31","author":"Porta-Sales","year":"2017","journal-title":"Palliat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3803\/EnM.2022.1427","article-title":"Real-world safety and effectiveness of denosumab in patients with osteoporosis: a prospective, observational study in South Korea","volume":"37","author":"Rhee","year":"2022","journal-title":"Endocrinol. Metab. Seoul."},{"key":"B19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cden.2013.12.006","article-title":"Antiresorptive drug-related osteonecrosis of the jaw","volume":"58","author":"Uyanne","year":"2014","journal-title":"Dent. Clin. North Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and drug administration's adverse event reporting system (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Bone Min. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1339721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T09:18:33Z","timestamp":1726132713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1339721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":23,"alternative-id":["10.3389\/fphar.2024.1339721"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1339721","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"article-number":"1339721"}}